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Space Motion Sickness (SMS) is commonly experienced by astronauts and often requires treatment with 
medications during the early flight days of a space mission. Bioavailability of oral (PO) SMS medications is often 
low and highly variable; additionally, physiological changes in a microgravity environment exacerbate variability 
and decrease bioavailability. These factors prompted NASA to develop an intranasal dosage form of scopolamine 
(INSCOP) suitable for the treatment of SMS.  However, to assure safety and efficacy of treatment in space, NASA 
physicians prescribe commercially available pharmaceutical products only.  Development of a pharmaceutical 
preparation for clinical use must follow distinct clinical phases of testing, phase I through IV to be exact, before it 
can be approved by the FDA for approval for clinical use. 
 
After a physician sponsored Investigative New Drug (IND) application was approved by the FDA, a phase 
I clinical trial of INSCOP formulation was completed in normal human subjects and results published.  The current 
project includes three phase II clinical protocols for the assessment of pharmacokinetics and pharmacodynamics 
(PK/PD), efficacy, and safety of INSCOP.  Three clinical protocols that were submitted to FDA to accomplish the 
project objectives: 1) 002 – A, a FDA Phase II dose ranging study with four dose levels between 0.1 and 0.4 mg in 
12 subjects to assess PK/PD, 2) 002 – B, a phase II clinical efficacy study in eighteen healthy subjects to compare 
efficacy of 0.2 (low dose) and 0.4 mg (high dose) INSCOP for prophylactic treatment  of motion-induces (off-axis 
vertical rotation) symptoms, and (3) 002 – C, a phase II clinical study with twelve subjects to determine 
bioavailability and pharmacodynamics of two doses (0.2 and 0.4 mg) of INSCOP in simulated microgravity, 
antiorthostatic bedrest.   
 
All regulatory procedures were competed that include certification for Good laboratory Procedures by 
Theradex®,  clinical documentation, personnel training, selection of clinical research operations contractor, data 
capturing and management, and annual reporting of results to FDA were successfully completed. Protocol 002 – A 
was completed and sample and data analysis is currently in progress.  Protocol 002 – B is currently in progress at 
Dartmouth – Hitchcock Medical Center and Protocol 002 – C has been submitted to the FDA and will be 
implemented at the same contractor site as 002 - A. An annual report was filed as required by FDA on the results of 
Protocol 002 – A.  
 
 Once all the three Phase II protocols are completed, a New Drug Administration application will be filed 
with FDA for Phase III clinical assessment and approval for marketing of the formulation.  A commercial vendor 
will be identified for this phase.  This is critical for making this available for treatment of SMS in astronauts and 
military personnel on duty.  Once approved by FDA, INSCOP can be also used by civilian population for motion 
sickness associated with recreational travel and other ailments that require treatment with anticholinergic drugs. 
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